Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Boehringer Ingelheim
Moodys
Baxter
Harvard Business School

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Empagliflozin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00881530 Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension Completed Boehringer Ingelheim Phase 2 2009-03-01 The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.
NCT00885118 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM) Completed Boehringer Ingelheim Phase 2 2009-04-01 The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
NCT01001962 Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics Not yet recruiting Aristotle University Of Thessaloniki Phase 4 2016-01-01 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT01111318 Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function Completed Boehringer Ingelheim Phase 1 2010-07-01 The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.
NCT01111331 Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers Completed Boehringer Ingelheim Phase 1 2010-05-01 The objective of the current study is to investigate the bioavailability of BI 10773 and of warfarin after concomitant multiple oral administration of BI 10773 and a single oral dose of warfarin in comparison to BI 10773 and warfarin given alone, and to investigate the pharmacodynamics of a single oral dose of warfarin with and without concomitant multiple oral administration of BI 10773.
NCT01131676 BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). Completed Eli Lilly and Company Phase 3 2010-07-01 The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Empagliflozin

Condition Name

Condition Name for Empagliflozin
Intervention Trials
Diabetes Mellitus, Type 2 46
Healthy 29
Heart Failure 12
Type 2 Diabetes Mellitus 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Empagliflozin
Intervention Trials
Diabetes Mellitus 93
Diabetes Mellitus, Type 2 79
Heart Failure 19
Diabetes Mellitus, Type 1 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Empagliflozin

Trials by Country

Trials by Country for Empagliflozin
Location Trials
United States 482
Canada 98
Germany 50
Australia 20
Japan 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Empagliflozin
Location Trials
Texas 29
Florida 25
California 24
Georgia 23
Ohio 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Empagliflozin

Clinical Trial Phase

Clinical Trial Phase for Empagliflozin
Clinical Trial Phase Trials
Phase 4 39
Phase 3 41
Phase 2/Phase 3 4
[disabled in preview] 77
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Empagliflozin
Clinical Trial Phase Trials
Completed 60
Recruiting 49
Not yet recruiting 39
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Empagliflozin

Sponsor Name

Sponsor Name for Empagliflozin
Sponsor Trials
Boehringer Ingelheim 85
Eli Lilly and Company 47
University Hospital, Basel, Switzerland 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Empagliflozin
Sponsor Trials
Industry 151
Other 105
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Medtronic
Colorcon
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.